NICE RECOMMENDATION ON TAXOL

Motion Text

at end add 'but is extremely concerned about the effect on breast cancer patients of the additional delay in issuing guidance on the use of taxanes for the treatment of breast cancer; recognises that it is estimated that several hundred women will continue to be denied these anti-cancer drugs in the delay period alone, some of whom may die prematurely as a result of the delay in publishing guidance; and joins the Cancer Research Campaign in calling on the National Institute for Clinical Excellence to approve Taxotere while the appeal into Taxol takes place, so that women eho do not have the benefit of time can start to be treated efficiently and effectively with this drug.'.